Dermatology Dialogues | Gaining and Maintaining Flare Control in Moderate-to-Severe Atopic Dermatitis: Enhancing Patient Quality of Life

Estimated Time
1.0 hr

Release Date
Dec 22, 2023

Expiration Date
Dec 21, 2024

This 4 part-15 minute segmented vodcast/podcast will unite dermatology and allergy clinicians, who provide care for patients with moderate-to-severe atopic dermatitis (M-S AD). Patients with M-S AD often experience disease-related flare events, which can have a substantial impact on quality of life. However, advancements in systemic biologic agents have shown promise regarding their efficacy to the treatment and long-term management of flare events with minimal impact on patient safety. Expert faculty, Peter Lio, MD, FAAD; Mark Boguniewicz, MD; TJ Chao, MPAS, PA-C; and Victoria Lazareth, MA, MSN, NP-C, DCNP will discuss how to choose treatment and manage patients with M-S AD to prevent flare events, the impact that the disease and flare events have on quality of life including how to best assess patient symptoms, and strategies that ensure shared decision-making and collaboration with interdisciplinary teams to ensure optimal clinical outcomes for patients.


Accreditation and Disclosure Information

Target Audience
This activity is intended for dermatologists/allergists, along with NPs and PAs, who are involved in the care of patients with M-S AD in the U.S.

Educational Objectives
After completing this activity, the participant should be better able to:

  • Accurately assess dermatology-specific quality of life factors when choosing and managing treatments throughout the progression of M-SAD to align with clinical guidelines
  • Select appropriate treatments by considering distinctions among drug mechanisms of action (MOA), efficacy, and safety data of both approved options and emerging biologic agents for M-S AD
  • Consistently apply shared decision-making in all patient discussions concerning treatment selection, modification, or intensification while accounting for quality of life through patient-reported outcome assessments

Program Agenda
Part 1: M-S AD Disease Burden, Disease Progression, and Treatment Challenges
Part 2: Current and Developing Systemic Agents for Treating M-S AD in Accordance with Clinical Guidelines
Part 3: Utilizing QOL and PRO Assessment to Enhance Clinical Outcomes in M-S AD Management
Part 4: Incorporating Shared Decision-Making in All Facets of Treatment Selection to Address QOL

Accreditation, Support and Credit



 Joint Accreditation with Commendation LogoIn support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Physician Associate Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 21, 2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Support Statement
This activity is supported by an educational grant from Lilly.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Peter Lio, MD, FAAD

Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, IL

Peter Lio, MD, FAAD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Almirall, Alphyn Biologics, Amyris, Inc., Apogee Therapeutics, Arbonne, Arcutis, Inc., ASLAN Pharmaceuticals, Bodewell, Boston Skin Science LLC, Bristol Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosciences, Dermavant Sciences, Inc., Dermira, DermVeda, Eli Lilly and Company, Galderma Laboratories, LP, Janssen Pharmaceuticals, Inc, Johnson & Johnson Consumer Products Company, Kimberly Clark, LEO Laboratories Ltd (LEO Pharma), Lipidor, L’Oreal USA Inc., Merck, Micreos Human Health B.V., Modernizing Medicine, MyOR Diagnostics Ltd, National Eczema Association, Regeneron, Sanofi US Services, Sibel Health, Skinfix, Inc., Sonica LLC, Suneco Technologies, Syncere Skin Systems, Theraplex, UCB, Unilever, Verdant Scientific Inc., Verrica Pharmaceuticals Inc, YobeeCare Inc.
Research Grant: AbbVie, AOBiome, LLC, Eczema Foundation (formerly La Fondation pour la Dermatite Atopique), National Eczema Association, Regeneron.
Speakers’ Bureau: AbbVie, Almirall, Arcutis Biotherapeutics, Eli Lilly and Company, Galderma USA, Hyphens Pharma, Incyte Corporation, La Roche-Posay Laboratorie Pharmaceutique, LEO Pharma, MyOR Diagnostics Ltd, Pfizer, Pierre Fabre Dermatologie, Regeneron, Verrica Pharmaceuticals Inc.
Stock Options: Boston Skin Science LLC, Codex Labs, Concerto Biosciences, DermVeda, LearnHealth/LearnSkin, Medable, Micreos Human Health B.V., Modernizing Medicine, Suneco Technologies, Syncere Skin Systems, Verdant Scientific Inc., YobeeCare Inc.
Other: National Eczema Association (Board of Directors), ParentMD (patent/royalties), Theraplex (patent/royalties).

Mark Boguniewicz, MD

Professor, Division of Allergy-Immunology,
Department of Pediatrics,
National Jewish Health and University of Colorado School of Medicine
Denver, CO

Mark Boguniewicz, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Amgen, ASLAN, Dermavant, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi Genzyme
Research Grant: Incyte, Regeneron, Sanofi Genzyme

T.J. Chao, MPAS, PA-C

Physician Assistant
Atlanta North Dermatology
Woodstock, GA

T.J. Chao, MPAS, PA-C, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme
Speakers’ Bureau: AbbVie, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi Genzyme

Victoria Lazareth, MA, MSN, NP-C, DCNP

Dermatology Nurse Practitioner
Contemporary Dermatology
Marston Mills, MA

Victoria Lazareth, MA, MSN, NP-C, DCNP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: MauiDerm NP/PA; Boehringer Ingelheim, Bristol Myers Squibb, Incyte
Speakers’ Bureau: MauiDerm NP/PA, AANP, DNA, NPACE

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

If you have questions regarding your certificate, please contact For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.